X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated urinary tract infections (UTIs) and certain kinds of pneumonia acquired during hospital stays.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar candidates in Europe.
Lead Product(s): Golimumab
Therapeutic Area: Immunology Product Name: AVT05
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Alvotech
Deal Size: $343.4 million Upfront Cash: $60.1 million
Deal Type: Partnership May 24, 2023
Details:
Palmeux (paliperidone palmitate) is a second-generation antipsychotic, also known as an atypical antipsychotic (simultaneous serotonin and dopamine antagonist) for the treatment of schizophrenia in adult patients.
Lead Product(s): Paliperidone Palmitate
Therapeutic Area: Psychiatry/Psychology Product Name: Palmeux
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
Under the terms of the agreement, Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand and Alvotech will be responsible for development and manufacture.
Lead Product(s): Omalizumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AVT23
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2023
Details:
AT-007 (gavorestat) is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG.
Lead Product(s): Govorestat
Therapeutic Area: Genetic Disease Product Name: AT-007
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Applied Therapeutics
Deal Size: $138.4 million Upfront Cash: $10.6 million
Deal Type: Partnership January 04, 2023
Details:
ADVANZ strengthens its specialty and hospital business by gaining an anti-infective portfolio from Sanofi made up of eight anti-infectives including Azactam (aztreonam), Cefotax, Claforan, Oroken, Rulid, Suprax, Wintriaxone and Colistimethate Sodique products.
Lead Product(s): Aztreonam
Therapeutic Area: Infections and Infectious Diseases Product Name: Azactam
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 03, 2022
Details:
ADVANZ PHARMA receives the exclusive rights for the commercialization of PolyPid’s lead drug candidate, D-PLEX100 (doxycycline hyclate) for the prevention of surgical site infections (“SSIs”) in abdominal and cardiac surgeries, in Europe.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: PolyPid
Deal Size: $112.5 million Upfront Cash: $2.6 million
Deal Type: Licensing Agreement August 03, 2022
Details:
OCALIVA (obeticholic acid), a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC). OCALIVA is contraindicated in PBC patients with decompensated cirrhosis.
Lead Product(s): Obeticholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Ocaliva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Intercept Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $405.0 million
Deal Type: Divestment July 01, 2022
Details:
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® (Obeticholic Acid) for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept.
Lead Product(s): Obeticholic Acid,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Ocaliva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Intercept Pharmaceuticals
Deal Size: $450.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition May 05, 2022
Details:
Ceftobiprole medocaril, Zevtera, is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nordic Capital
Deal Size: $846.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
